Paras Healthcare IPO opens today: Check GMP, price band and key details
Paras Healthcares Rs 1,450 crore IPO opens for subscription on October 21 and closes on October 23, with a grey market premium (GMP) of around 7%. The issue comprises a fresh issue of Rs 500 crore and an offer for sale (OFS) of Rs 950 crore.
Paras Healthcare IPO opens for subscription today, October 21, 2026, offering investors a three-day bidding window until October 23. In the grey market, the IPO is commanding a GMP of 7% over its issue price.The Rs 1,450 crore public issue is a combination of a fresh issue of 72.15 lakh shares worth Rs 500 crore and an offer for sale (OFS) of 1.37 crore shares aggregating to Rs 950 crore.The allotment for Paras Healthcare IPO is expected to be finalised on October 26, while the shares are tentatively scheduled to list on the BSE and NSE on October 28, 2026.The company has fixed the IPO price band at Rs 660-693 per share.
The lot size is 21 shares, translating into a minimum investment of Rs 14,553 for retail investors applying at the upper end of the price band.JM Financial Ltd., BofA Securities India Ltd. and Nuvama Wealth Management Ltd. are the book-running lead managers for the issue, while MUFG Intime India Pvt. Ltd. is the registrar.Live EventsAnchor Investors: Paras Healthcare raised Rs 652.5 crore from anchor investors on October 19, a day before the opening of its maiden public issue.
The investors included Abu Dhabi Investment Authority, BlackRock Global Funds, Eastspring Investments, Government Pension Fund Global, Natixis International Funds, Integrated Core Strategies (Asia) and Citigroup Global.Paras Healthcare IPO GMP TodayParas Healthcare IPO is commanding a grey market premium (GMP) of Rs 50, or around 7%, over the upper price band of Rs 693 per share. Based on the current GMP, the estimated listing price stands at approximately Rs 743 per share.IPO Objects of the IssueThe company plans to utilise Rs 320.90 crore from the net proceeds of the IPO to prepay or repay, either fully or partially, certain outstanding borrowings availed by the company.
Additionally, Rs 54.10 crore will be invested in its wholly owned subsidiary, PMHPL, which operates a hospital in Srinagar, to facilitate the full or partial repayment or prepayment of its outstanding borrowings.The remaining proceeds will be allocated towards general corporate purposes. Of the total IPO proceeds of Rs 375 crore, the primary objective is to reduce the company's debt burden, strengthen its financial position and support its overall corporate requirements.Financials PerformanceParas Healthcare Ltd. reported a 24% year-on-year increase in total income to Rs 1,629 crore in FY26, compared with Rs 1,314 crore in FY25.
The company also turned profitable, posting a profit after tax (PAT) of Rs 44 crore in FY26, against a loss of Rs 58 crore in the previous financial year.About Paras HealthcareIncorporated in1987, Paras Healthcare Limited is a leading clinical specialty-led hospital platform providing tertiary and quaternary healthcare services across North India, Bihar, and Jharkhand under the "Paras Health" brand.
The company operates eight hospitals with an aggregate bed capacity of 2,211 beds across Gurugram, Panchkula, Patna, Darbhanga, Kanpur, Udaipur, Ranchi, and Srinagar as of June 30, 2026.It specializes in cardiac sciences, oncology, neurosciences, gastro sciences, orthopedics & sports injury, and renal sciences (CONGOR specialties), which contributed 75.30% of revenue in Fiscal 2026. Paras Healthcare has over 20 years of operating history and follows a balanced growth strategy through mature, emerging, and new hospitals.
The company plans to expand its network with a 300-bed hospital in Gurugram and a 500-bed hospital in Ludhiana, increasing total capacity to 3,011 beds by March 2028.As of March 31, 2026, it had 4,670 employees, including 1,084 doctors and 1,937 nurses.Disclaimer: The views/recommendations mentioned in this article, wherever applicable, are those of the respective SEBI-registered Research Analyst/brokerage and have been reproduced/reported with due attribution.
They should not be construed as the views or recommendations of The Economic Times Digital or the journalist. Readers are advised to consider the original research report and make their investment decisions based on their own assessment. Brokerage disclaimers here(You can now subscribe to our ETMarkets WhatsApp channel)
